RxDoctor Payments Data

Robert Black, MD

Cardiovascular Disease · Dunedin, FLNPI 1508826785

Payments from drug & device makers

$179,130in general payments, 2019–2025

Across 453 payments — averaging $395.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$120K
  • AstraZeneca$46K
  • Bayer$5K
  • Exo Imaging, Inc.$4K
  • Novartis$651
  • Amgen$573
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$113,69688%
  • Travel & lodging$2,6962%
  • Food & beverage$8,7477%
  • Education$420%
  • Gifts$500%
  • Other$3,5003%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,130 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$430,320
Medicare patients
1,557
Services billed
4,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban663$688,860
EliquisApixaban298$319,627
Repatha SureclickEvolocumab128$93,383
EntrestoSacubitril/Valsartan57$81,781
MultaqDronedarone Hcl19$32,967
BrilintaTicagrelor30$29,016
JardianceEmpagliflozin15$20,837
Atorvastatin Calcium1,365$12,360
Metoprolol Succinate868$11,657
Dabigatran EtexilateDabigatran Etexilate Mesylate26$7,391
Flecainide Acetate117$5,470
Repatha SyringeEvolocumab20$5,365
Rosuvastatin Calcium300$4,901
ClopidogrelClopidogrel Bisulfate344$4,879
Ezetimibe239$4,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$120,347$688,860663 claims
PfizerEliquis$539$319,627298 claims
NovartisEntresto$651$81,78157 claims
Sanofi-aventis U.S. LLCMultaq$139$32,96719 claims
AstraZenecaBrilinta$45,658$29,01630 claims
Boehringer IngelheimJardiance$371$20,83715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Dunedin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →